ReachMD
CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Mindenképp látogasd meg a podcast oldalát, és támogasd a készítőjét: reachmd.com
Hol hallgathatod?
Podcastok az alkalmazásban Replaio Radio HamarosanA podcastok hamarosan megérkeznek az alkalmazásba. Telepítsd most, és láss elsőként egy teljesen új megközelítést a podcastokhoz
Telepítsd ingyen
Android közel 10 M letöltés · 4,8-as értékelés
iOS hamarosan
Epizódok
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics 25.04.2025 29:30
Host: Carlos M. de Castro, MD Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by hemolytic anemia and associated with thrombophilia and bone marrow failure. Early and accurate diagnosis and classification of PNH is essential to optimize outcomes. However, the diagnosis of PNH may be delayed or missed for months or even years in practice, and only 25% of newly...
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC 31.03.2025 5:30
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes 31.03.2025 5:45
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond 31.03.2025 5:15
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
From Guidelines to Practice: First-Line Treatment Choices in mCRC 31.03.2025 5:30
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection 31.03.2025 5:45
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC 31.03.2025 5:30
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes 31.03.2025 5:45
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond 31.03.2025 5:15
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
From Guidelines to Practice: First-Line Treatment Choices in mCRC 31.03.2025 5:30
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection 31.03.2025 5:45
Host: Fortunato Ciardiello, MD, PhD Host: Jenny Seligmann, MBChB, PhD This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
Key Patient Counseling Issues Surrounding FNAIT and Its Risk in Subsequent Pregnancies 31.01.2025 5:00
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Nipocalimab: An FcRn Inhibitor and Its Role in Treating HDFN 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Neonatal FcRn Inhibition: A New Pathway for Addressing the Alloimmune Disorders of Pregnancy 31.01.2025 3:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Screening for FNAIT: Anticipating HPA-1a Incompatibility 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Managing the “Next Pregnancy” in Patients With an FNAIT-Affected First Child 31.01.2025 5:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Current Management Strategies for FNAIT 31.01.2025 5:00
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Current Diagnostic Signs, Symptoms, and Lab Tests for FNAIT 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Classification/Suspecting a Diagnosis of FNAIT/NAIT 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): The Platelet Equivalent of Rh Disease 31.01.2025 5:15
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
The Alloimmune Disorders of Pregnancy 31.01.2025 3:30
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Key Patient Counseling Issues Surrounding FNAIT and Its Risk in Subsequent Pregnancies 31.01.2025 5:00
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Nipocalimab: An FcRn Inhibitor and Its Role in Treating HDFN 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Neonatal FcRn Inhibition: A New Pathway for Addressing the Alloimmune Disorders of Pregnancy 31.01.2025 3:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Screening for FNAIT: Anticipating HPA-1a Incompatibility 31.01.2025 4:45
Guest: Karin J. Blakemore, MD Guest: Emilie L. Vander Haar Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve...
Hasonló podcastok
Hallgasd a(z) CME/CE podcastot a Replaióban
Rádió és podcastok egy alkalmazásban - ingyen és regisztráció nélkül. Telepítsd még ma, és ne maradj le a premierről
A Replaio nem podcastkiadó; a műsorok nevei, borítóképei és hanganyagai a szerzőiket illetik, és nyilvános RSS-csatornákon keresztül terjednek.
